|Table of Contents|

Efficacy of medroxyprogesterone acetate treatment of castrate-resistant prostate cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 02
Page:
246-248
Research Field:
Publishing date:

Info

Title:
Efficacy of medroxyprogesterone acetate treatment of castrate-resistant prostate cancer
Author(s):
Shen Zhiyong1; Wang Ling1; Cheng Huihua1; Fu Zhichao1; Liao Shaoguang1; Luo Huachun1; Lei Yong2
1.Department of Radiation；2.Department of Medical Affairs,Fuzhou General Hospital，Dongfang Hospital Affiliated to Xiamen University,Fujian Fuzhou 350025,China.
Keywords:
medroxyprogesterone; castrate-resistant prostate cancer (CRPC); quality of life; efficacy
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2017.02.022
Abstract:
Objective:To observe the efficacy and side effects of medroxyprogesterone in castrate-resistant prostate cancer (CRPC).Methods:PSA,KPS score,hemoglobin,nutritional status,and drug toxicity were evaluated in 62 CRPC patients before and after orally taking medroxyprogesterone.Results:After orally taking medroxyprogesterone,PSA decreased in 7 patients(11.3%),and remained stable in 15 patients(24.2%).KPS score and hemoglobin were improved significantly (P＜0.05).The nutritional status were improved in 40 patients(64.5%),and remained stable in 19 patients(30.6%).No III-IV grade toxic and side effects were found.Six patients had mild hyponatremia,five patients had mild hypokalemia,four patients had Ⅰdegree lower limb edema after treatment.Conclusion:Medroxyprogesterone may slow the progression of the PSA,improve the quality of life with few drug side effects in advanced CRPC patients.

References:

［1］ Siegel R,Ma J,Zou Z,et al.Cancer statistics,2014［J］.CA Cancer J Clin,2014,64(1):9-29.
[2] Han SJ,Zhang SW,Chen WQ,et al.Analysis of the status and trends of prostate cancer incidence in China［J］.Chin Clin Oncol,2013,18(4):330-334.［韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析［J］.临床肿瘤学杂志,2013,18(4):330-334.］
[3] Gaya JM,Ahallal Y,Sanchez-Salas R,et al.Current,new and novel therapy for castration-resistant prostate cancer［J］.Expert Rev Anticancer Ther,2013,13(7):819-827.
[4] Heidenreich A,Aus G,Bolla M,et al.EAU guidelines on prostate cancer［J］.Eur Urol,2008,53(1):68-80.
[5] Heidenreich A,Bastian PJ,Bellmunt J,et al.EAU guidelines on prostate cancer.Part II:Treatment of advanced,relapsing,and castration-resistant prostate cancer［J］.Eur Urol,2014,65(2):467-479.
[6] Janjan N,Lutz ST,Bedwinek JM,et al.Therapeutic guidelines for the treatment of bone metastasis:A report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology［J］.Palliat Med,2009,12:417-426.
[7] Na Yanqun,Ye Zhangqun,Sun Yinghao,et al.Guidelines for diagnosis and treatment of diseases in the Department of Urology (2014 edition)［M］.Beijing:People's Health Publishing House，2014：62-89.［那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版)［M］.北京:人民卫生出版社,2O14:61-89.］
[8] Sun Yan.Clinical oncology department of internal medicine manual［M］.Beijing:People's Health Publishing House，2007：142-145.［孙燕.临床肿瘤内科手册［M］.北京:人民卫生出版社,2007：142-145.］
[9] Mizokami A,Namiki M.Reconsideration of progression to CRPC during androgen deprivation therapy［J］.J Steroid Biochem Mol Biol,2015,145:164-171.
[10] Montgomery RB,Mostaghel EA,Vessella R,et al.Maintenance of intratumoral androgens in metastatic prostate cancer:A mechanism for castration-resistant tumor growth［J］.Cancer Res,2008,68(11):4447-4454.
[11] Mulholland DJ,Kobayashi N,Ruscetti M,et al.Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells［J］.Cancer Res,2012,72(7):1878-1889.
[12] Conteduca V,Aieta M,Amadori D,et al.Neuroendocrine differentiation in prostate cancer:Current and emerging therapy strategies［J］.Crit Rev Oncol Hematol,2014,92(1):11-24.
[13] Cookson MS,Roth BJ,Dahm P,et al.Castration-resistant prostate cancer:AUA guideline［J］.J Urol,2013,190(2):429-438.
[14] Mostaghel EA.Abiraterone in the treatment of metastatic castration-resistant prostate cancer［J］.Cancer Manag Res,2014,6:39-51.
[15] Sanford M.Enzalutamide:A review of its use in metastatic,castration-resistant prostate cancer［J］.Drugs,2013,73(15):1723-1732.
[16] Peer A,Gottfried M,Sinibaldi V,et al.Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel［J］.Prostate,2014，74(4):433-440.
[17] Lei JX,Li LJ,Pan CF.To observe the curative effect of megestrol acetate on quality of life of patients with advanced cancer［J］.Foreign Med Oncol,2002,29(3A):53-55.［类健翔,李林均,潘车风.甲地孕酮改善晚期癌症患者生活质量的疗效观察［J］.国外医学肿瘤学分册,2002,29(3A):53-55.］

Memo

Memo:
-
Last Update: 2016-12-01